Company Profile

Sarepta Therapeutics Stock Price, News & Catalysts

Ticker:
SRPT
Exchange:
NASDAQ
Sector:
Gene Therapy
Location:
United States

Stock performance

14.17 USD (-2.48%)

Close

Last updated: November 19, 2026

1.72B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SRPT closed down 2.48% at $14.17. No new same-company headline was identified in the current news window.

Company overview

Precision Genetic Medicine

Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.

ELEVIDYS

ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.

Exon-Skipping Franchise

EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.

siRNA Platform

SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

Global Commercial Partnerships

Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.

Future catalysts

  • Multiple-ascending-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD in the fourth quarter of 2026.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics (SRPT) most recently closed at 14.17 USD, a -2.48% move versus the previous session.

What is the market cap of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics currently has a market capitalization of 1.72B USD on BioPharmSignal.

What does Sarepta Therapeutics do?

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and...

On which exchange is SRPT stock listed?

Sarepta Therapeutics (SRPT) is associated with NASDAQ, United States, Gene Therapy.

What is SRP-1001?

Multiple-ascending-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD in the fourth quarter of 2026.

Which conditions is Sarepta Therapeutics targeting with SRP-1001?

Sarepta Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.

How does Sarepta Therapeutics describe recent progress with SRP-1001?

Multiple-ascending-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD in the fourth quarter of 2026.

What is SRP-1003?

siRNA Platform SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.